摘要
本研究基于药品全生命周期、供应链理论与利益相关者理论,构建罕见病用药可及性管理分析框架,从可获得性、可供应性、可利用性与可负担性管理4个方面比较分析美国、欧盟、日本及部分发展中国家和地区管理办法的异同,并结合我国国情提炼出国际经验对我国开展罕见病用药可及性管理的启示。
Based on the whole life cycle of drugs,supply chain theory,and stakeholder theory,this study constructed an analytical framework for the accessibility management of orphan drugs,compared and analyzed the similarities and differences of the management approaches in the United States,the European Union,Japan,and some developing countries and regions from four aspects:availability,supplyability,utilizability,and affordability management.Combined with the specific national conditions of China,the implications of the international experience were extracted for the conduction of accessibility management of orphan drugs in China.
作者
张奇林
庞昕
马黎黎
ZHANG Qi-lin;PANG Xin;MA Li-li(Center for Social Security Studies of Wuhan University,Wuhan 430072,China;National Health Commission,Beijing 100044,China)
出处
《中国新药杂志》
北大核心
2025年第2期123-129,共7页
Chinese Journal of New Drugs
基金
教育部人文社会科学重点研究基地重大项目“共同富裕目标下第三次分配的理论建构与实现路径研究”(22JJD630016)。
关键词
罕见病
罕见病用药
可及性
国际比较
rare diseases
orphan drug
accessibility
international comparison
